Warfarin: History, tautomerism and activity

Journal of Computer-Aided Molecular Design

Volumn 24, Issue 6-7, 2010, Pages 553-573

  Porter, William R ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

Keto enol tautomerism; Ring chain tautomerism; Tautomers; Warfarin

Indexed keywords

ANTI-COAGULANT DRUGS; BIOLOGICAL PROPERTIES; COMPUTATIONAL SOFTWARE; IONIZATION CONSTANT; KETO-ENOL TAUTOMERISM; OCTANOL-WATER PARTITION COEFFICIENT; RING-CHAIN TAUTOMERISM; TAUTOMER; TAUTOMERIC FORMS; WARFARIN;

BIOCHEMISTRY;

4 HYDROXYCOUMARIN DERIVATIVE; CYTOCHROME P450 2C9; OCTANOL; UNCLASSIFIED DRUG; WARFARIN; WARFARIN DERIVATIVE; WATER; ANTICOAGULANT AGENT;

COMPUTER PROGRAM; CONSTANTS AND COEFFICIENTS; DRUG ACTIVITY; DRUG METABOLISM; ENANTIOMER; HUMAN; IONIZATION CONSTANT; ISOMERISM; NONHUMAN; PARTITION COEFFICIENT; PKA; PRIORITY JOURNAL; PROTEIN BINDING; REVIEW; TAUTOMERIC SHIFT; ANIMAL; CHEMISTRY; METABOLISM; STEREOISOMERISM;

ANIMALS; ANTICOAGULANTS; HUMANS; ISOMERISM; STEREOISOMERISM; WARFARIN;

EID: 77955712703     PISSN: 0920654X     EISSN: 15734951     Source Type: Journal    
DOI: 10.1007/s10822-010-9335-7     Document Type: Review

References (119)

1. Lamb E (2009) Top 200 prescription drugs of 2008. Pharmacy Times, Plainsboro. http://www.pharmacytimes.com/issue/pharmacy/2009/2009-05/ RxFocusTop200Drugs-0509. Accessed 08 Mar 2010
2. Ikawa M, Stahman MA, Link KP (1944) 4-Hydroxycoumarins. V. Condensation of α, β-unsaturated ketones with 4-hydroxycoumarin. J Am Chem Soc 66:902-906
3. Overman RS et al (1944) Studies on the hemorrhagic sweet clover disease: XII.I. Anticoagulant activity and structure in the 4-hydroxycoumarin group. J Biol Chem 153:5-24
4. Schofield FW (1922) A brief account of a disease of cattle simulating haemorrhagic septicaemia, due to feeding sweet clover. Can Vet Rec 3:74-78
5. Roderick LM (1929) The pathology of sweet clover disease in cattle. J Amer Vet Med Ass 74:314-325
6. Burris RH (1994) Biographical memoir of Karl Paul link, vol 65. Biographical Memoirs, National Academy of Sciences, Washington, DC, pp 176-195
7. https://www.warf.org/about/index.jsp?cid=26&scid=34. Accessed Jan 2010
8. Link KP (1959) The discovery of dicumarol and its sequels. Circulation 19:97-107
9. Campbell HA, Link KP (1941) Studies on the hemorrhagic sweet clover disease. I.V. The isolation and crystallization of the hemorrhagic agent. J Biol Chem 138:21-33
10. Stahmann MA, Huebner CF, Link KP (1941) The hemorrhagic sweet clover disease. V. Identification and synthesis of the hemorrhagic agent. J BiolChem 138:513-527
11. Meyer OO (1959) Historical data regarding the experiences with coumarin anticoagulants at the University of Wisconsin Medical School. Circulation 19:114-117
12. Scheel LD (1949) Studies on the anticoagulant dicumarol and other 4-hydroxycoumarins. Sect, II, The anticoagulant activity and toxicity of 3-substituted-4-hydroxycoumarins. PhD Thesis, University of Wisconsin
13. Wines M (2003) New study supports idea that Stalin was poisoned. The New York Times, 5 March
14. Wu DL (1949) Masters Thesis, University of Wisconsin; Scheel LD, Wu D, Link KP (1949) Abstracts of papers, 116th meeting of the American Chemical Society
15. Seidman M (1950) Studies on 3-(a-phenyl-b-acetylethyl)-4-hydroxycoumarin. PhD Thesis, University of Wisconsin
16. Bravic G, Gaultier J, Hauw C (1973) Crystal structure of an antivitamin K, warfarin. C R Acad Sci Paris Ser C 277(22): 1215-1218
17. Valente EJ, Trager WF, Jensen LH (1975) Crystal and molecular structure and absolute configuration of (-)-(S)-warfarin. Acta Cryst B B31(4):954-960
18. Halland N, Hansen T, Jørgensen KA (2003) Organocatalytic asymmetric Michael reaction of cyclic 1, 3-dicarbonyl compounds and alpha, beta-unsaturated ketones-a highly atomeconomic catalytic one-step formation of optically active warfarin anticoagulant. Angew Chem Int Ed Engl 42(40):4955-4957
19. Shahzadi S, Ali S, Asif I, Ashraf R, Jin G-X (2006) The mechanism and crystal structure of 2-methoxy-2-methyl-4- phenyl-3, 4, 4a, 10b-tetrahydro-2H, 5H-pyrano[3, 2-c]chromen- 5-one. Acetal of warfarin acid. Turkish J Chem 30(6):703-709
20. Porter WR (1976) Synthesis, structure in solution and stereochemical aspects of the microsomal metabolism of warfarin and phenprocoumon. PhD Thesis, University of Washington
21. Link KP (1957) Warfarin-alkali metal derivatives and processes of preparing the same. US patent 2777859
22. Schroeder CH, Link KP (1963) Warfarin sodium. US patent 3077481;
23. Schroeder CH, Link KP (1963) Warfarin sodium. US patent 3077481; Weiner N, Park R, Johnson M, Schoeder CH, Link KP (1966) Preparation of crystalline warfarin sodium-isopropyl alcohol complex. US patent 3246013
24. Hiskey CF, Melnitchenko V (1965) Clathrates of sodium warfarin. J Pharm Sci 54(9):1298-1302
25. Sheth AR, Young VG Jr, Grant DJW (2002) Warfarin sodium 2- propanol solvate. Acta Cryst E58:m197-m199
26. Sheth AR, Brennessel WW, Young VG Jr, Muller FX, Grant DJW (2004) Solid-state properties of warfarin sodium 2-propanol solvate. J Pharm Sci 93(11):2669-2680
27. Huebner CF, Link KP (1945) 4-hydroxycoumarin. VI.I. Reactions of 4-hydroxycoumarin with cationoid reagents. J Amer Chem Soc 67:99-102
28. Arndt F, Loewe L, Un R, Ayca E (1951) Coumarindiol and coumarin-chromone tautomerism. Chem Ber 84:319-329
29. Klosa J (1953) Possibility of tautomeric forms of 4-hydroxycoumarin. Arch Pharm 286:37-43
30. Chmielewska I, Cieslak J (1958) Vitamins and antivitamins K: tautomerism of dicoumarol. Tetrahedron 4:135-146
31. Jachymczyk W, Cieslak J, Chmielewska I (1960) Tautomerism of dicoumarol. Three isomeric methyl ethyl ethers of dicoumarol. Rocz Chem 34:925-930
32. Knobloch E, Kakac B, Macha F (1952) Anticoagulants. XVII.I. A study of the tautomeric equilibria of effective anticoagulant derivatives of 4-hydroxycoumarin. Chem Listy 46:416-419
33. Chmielewska J, Ciecierska D (1952) K vitamins and antivitamins. V. Ultraviolet absorption spectra of biologically active derivatives of 4-hydroxycoumarin. Przemysl Chem 31:253-256
34. Dezelic M, Trkovik M, Zovko M (1963) Absorption spectra of coumarins. Glasnik Hemicara Techol Bosne Hercegovina 12:17-44
35. Perel'son ME, Sheinker YuN (1966) Spectra and structure of hydroxycoumarin and hydroxyfurocoumarin salts. Zh Prikl Spektosk 5(1):104-110
36. Khaikin MS, Rakova NF (1968) Ultraviolet spectra of some 6, 7- and 7, 8-dihydroxycoumarins. Zh Prikl Spektrosk 8(6):1063-1066
37. Masrani KV, Rama HS, Bafna SK (1974) Ultaviolet absorption spectra: substituted coumarins. J Appl Chem Biotechnol 24(6):331-341
38. Knobloch E, Prochzka Z (1953) Studies on anticoagulants. X.X.V. Infrared spectra of some derivatives of 4-hydroxycoumarin and chromone. Chem Listy 47:1285-1292
39. Abramovich RA, Gear JR (1958) Unsymmetrically substituted 3, 30-methylene bridged 2, 20-dihydroxychromones. Can J Chem 36:1501-1510
40. Farmer VC (1959) Spectra and structure of 4-hydroxycoumarins. Spectrochim Acta 10:870-882
41. Hutchinson DW, Tomlinson JA (1969) Structure of dicumarol and related compounds. Tetrahedron 25(12):2531-2537
42. Gaultier J, Hauw C (1965) Structure of an "antivitamin" K, 3- bromo-4-hydroxycoumarin monohydrate. Compt Rend 260(13(Groupe 8)):3666-3667;
43. Gaultier J, Hauw C (1965) Crystalline and molecular structure of 3-bromo-4-hydroxycoumarin monohydrate. Acta Cryst 19(6):927-933
44. Gaultier J, Hauw C (1965) Crystal structure of monohydrated 4- hydroxycoumarin. Compt Rend 260(22(Groupe 8)):5787-5789;
45. Gaultier J, Hauw C (1966) Structure of 4-hydroxycoumarin. Water of hydration and crystal cohesion. Acta Cryst20(5):646-651
46. Bravic G, Gaultier J, Hauw C (1968) Crystalline and molecular structure of dicoumarol [3, 3'-methylenebis(4-hydroxycoumarin)]. C R Acad Sci Paris 267(26):1790-1793
47. Bravic G, Gaultier J, Hauw C (1971) Crystalline and molecular structure of marcoumar. C R Acad Sci Paris 272(12):1112-1114
48. Alcock NW, Hough E (1972) The crystal and molecular structure of 3, 30-methylene(bis-6-bromo-4-hydroxycoumarin): unusual molecular interactions. Act Cryst B28(6):1957-1960
49. Bravic G, Gaultier J, Geoffre S, Hauw C (1974) Crystal structure of an antivitamin K. 3-(1'a-Naphthyl)-4-hydroxycoumarin. C R Acad Sci Paris C27B:601-603
50. Valente EJ, Trager WF, Lingafelter EC (1976) (-)-3-(1-Phenylpropyl)- 4-hydroxycoumarin. Acta Cryst B32(1):277-279
51. Jones PR (1968) Ring-chain tautomerism. Chem Rev 63:461-487
52. Kol'tsov AI, Kheifets GM (1971) Investigation of keto-enol tautomerism by nuclear magnetic resonance spectroscopy. Russ Chem Rev 40(9):773-788
53. Schroeder CH, Titus ED, Link KP (1957) Synthetic approach to some 3-aralkyl-4-hydroxycoumarins. J Amer Chem Soc 79:3291-3292
54. Pohl LR, Haddock R, Garland WA, Trager WF (1975) Synthesis and thin-layer chromatographic, ultraviolet and mass spectral properties of the anticoagulant phenprocoumon and its monohydroxylated derivatives. J Med Chem 18(5):513-519
55. Chan KK, Lewis RJ, Trager WF (1972) Absolute configuration of the four warfarin alcohols. J Med Chem 15(12):1265-1270
56. Robertson DN, Linl KP (1953) Studies of 4-hydroxycoumarins. XI.I. 3-Substitued-aminoethyl-4-hydroxycoumarin derivatives by the Mannich reaction. J Amer Chem Soc 75:1883-1885
57. Sen K, Bagchi P (1959) Studies on the ultraviolet absorption spectra of coumarins and chromones. I.I. Hydroxy derivatives. J Org Chem 24:316-319
58. French WN, Wehrli MI (1965) Identification and assay of some coumarin anticoagulants. Can Pharm J 98(5):174-179
59. Mendez J, Lojo MI (1968) Spectral analysis of coumarins. Microchem J 13(3):506-512
60. Mehta MJ, Hegde RS, Bhatt RA, Patel DJ, Bafna SL (1969) Ultraviolet spectra: 4-hydroxycoumarins. J Appl Chem 19(1):29-30
61. Knight AR, McIntyre JS (1968) Deuterated 4-hydroxycoumarin derivatives. Can J Chem 46(11):1949-1951
62. Wheeler CR (1980) Warfarin and phenprocoumon as probes to distinguish inducible forms of cytochrome P-450. PhD Thesis, University of Washington
63. Perel'son ME, Zvolinskii VP, Kagan GI, YuN Sheinker (1973) Investigation of the electronic spectra of a-pyrone derivatives by the Pariser-Parr-Pople method in the variable b approximation. Zh Struckt Khim 14(2):246-254
64. Perel'son ME, Sheinker YuN, Zaitsev BF, Pozdyshev VA (1964) Integrated intensities of the carbonyl bands of a number of pyrones and quinones. Izv Akad Nauk SSSR Ser Khim (5):804-808
65. Perel'son ME, Sheinker YuN (1968) Structure of the alkali metal salts of hydroxycoumarins and hydroxyfurocoumarins and their MO LCAO calculation. Teor Eksp Khim 4(2):184-191
66. Ahuja VK, Kapoor KL, Ray NK (1973) Molecular orbital study of pyrones: part II-chromones. Indian J Chem 11(2):143-145
67. Ray NK, Ahuja VK (1973) Molecular orbital study of the photoreactivity of triplet coumarins. Photochem Photobiol 17(5):347-351
68. Ahuja VK, Kapoor KL, Ray NK (1973) Molecular orbital study of pyrones: part III-coumarins. Indian J Chem 11(5):458-460
69. Linke HAB (1969) Infrared spectra of hydroxychromone. Absorption of the carbonyl valence vibration. Spectrochim Acta 25A(6):1067-1074
70. Porter WR, Kunze K, Valente EJ, Trager WF (1980) The synthesis of C-2 isotopically labeled optically pure warfarin and phenprocoumon. J Label Comp Radiopharm 17(6):763-773
71. Obaseki AO, Porter WR, Trager WF (1982) 4-Hydroxycoumarin/ 2-hydroxychromone tautomerism: infrared spectra of 2-13C and 3-D labeled 4-hydroxycoumarin and its anion. J Heterocyclic Chem 19:385-390
72. Porter WR, Trager WF (1982) 4-Hydroxycoumarin/2-hydroxychromone tautomerism: Infrared spectra of 3-substituted-2- 13C-4-hydroxycoumarins. J Heterocyclic Chem 19:475-480
73. Chan KK, Giannini DD, Cain AH, Roberts JD, Porter WR, Trager WF (1977) Carbon-13 nuclear magnetic resonance studies of coumarin and related compounds. Tetrahedron 33:899-906
74. Valente EJ, Lingafelter EC, Porter WR, Trager WF (1977) The structure of warfarin in solution. J Med Chem 20(11):1489-1493
75. Valente EJ, Porter WR, Trager WF, (1978) Conformations of selected 3-substituted 4-hydroxycoumarins in solution by nuclear magnetic resonance. Warfarin and phenprocoumon. J Med Chem 21(2):231-234
76. Obaseki AO (1982) Improved synthesis, separation and quantitation of warfarin and its metabolites and their use in the study of the tautomerization of 4-hydroxycoumarins and the metabolism of warfarin. Chapter 2, PhD Thesis, University of Wisconsin
77. Obaseki AO, Porter WR (1987) Structure of warfarin analogs in solution. Arch Pharm Chem Sci Ed 5:110-121
78. Heimark LD, Trager WF (1984) The preferred solution conformation of warfarin at the active site of cytochrome P-450 based on the CD spectra in octanol/water model system. J Med Chem 27:1092-1095
79. Holbrook A, Pereira JA, Labiris R, Mcdonald H, Douketis JD, Crowther M, Wells PS (2005) Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 165:1095-1106
80. Mann KG (1999) Biochemistry and physiology of blood coagulation. Thromb Haemost 82(2):165-174
81. Garcia AA, Reitsma PH (2008) VOKORC1 and the vitamin K cycle. Vit Horm 78:23-33
82. Tie J-K, Stafford DW (2008) Structure and function of vitamin K epoxide reductase. Vit Horm 78:103-130
83. Wallin R, Wajih N, Hutson SM (2008) VKORC1: a warfarinsensitive enzyme in vitamin K metabolism and biosynthesis of vitamin K-dependent blood coagulation factors. Vit Horm 78:227-246
84. Thijssen HHW, Baars LGM, Vervoort-Peters HTM (1988) Vitamin K 2.3-epoxide reductase: the basis for steroselectivity of 4-hydroxycoumarin anticoagulant activity
85. Fasco MJ, Principe LM, Walsh WA, Friedman PA (1983) Warfarin inihibition of vitamin K 2, 3-epoxide reductase in rat liver. Biochem 22:5655-5660
86. Park BK (1988) Warafin: metabolismand mode of action. Biochem Pharmacol 37(1):19-27
87. Gebauer M (2007) Synthesis and structure-activity relationships of novel warfarin derivatives
88. He M, Korzekwa KR, Jones JP, Rettie AE, Trager WF (1999) Structural forms of phenprocoumon and warfarin that are metabolized at the active site of CYP2C9. Arch Biochem Biophys 372(1):16-28
89. Porter RS, Sawyer WT, Lowenthal DT (1986) Warfarin. In: Evans WE, Schentag JJ, Jusko WJ (eds) Applied pharmacokinetics, 2nd edn. Applied Therapeutics, Spokane, pp 1057-1104
90. Larsen FG, Larsen CG, Jakobsen P, Brodersen R (1985) Interaction of warfarin with human serum albumin: a stoichiometric description. Mol Pharmacol 27:263-270
91. Petitpas I, Bhattacharya AA, Twine S, East M, Curry S (2001) Crystal structure analysis of warfarin binding to human serum albumin: Anatomy of drug site I. J Biol Chem 276(25):22804-22809
92. Kaminsky LS, Zhang Z-Y (1997) Human P450 metabolism of warfarin. Pharmacol Ther 73(1):67-74
93. Black DJ, Kunze KL, Wienkers LC, Gidal BE, Seation TL, McDonnell AP, Evans SJ, Bauwens JE, Trager WF (1996) Warfarin-fluconazole. I.I. A metabolically based drug interaction: in vivo studies. Drug Metab Dispos 24:414-421
94. Aquilante CL, Langaee TY, Lopez LM, Yarandi HN, Tromberg JS, Mohuczy D, Gaston KL, Waddell CD, Chirico MJ, Johnson JA (2006) Influence of coagulation factor, vitamin K epoxide reductase complex sububnit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. Clin Pharmacol Thera 79(4):291-302
95. Yin T, Miyata Y (2007) Warfarin dos and the pharmacogenomics of CYP2C9 and VKORC1-rationale and perspectives. Thromb Res 120:1-10
96. Williams PA, Cosme J, Ward A, Angove HC, Vinkoviĉ DM, Jhotl H (2003) Crystal structure of human cytochrome P450 @C9 with bound warfarin. Nature 424(24):464-468
97. Jones JP, He M, Trager WF, Rettie AE (1996) Three-dimensional quantitative structure-activity relationship for inhibitors of cytochrome P4502C9. Drug Metab Dispos 24(1):1-6
98. Haining RL, Jones JP, Henne KR, Fisher MB, Koop DR, Trager WF, Rettie AE (1999) Enzymic determinants of the substrate specificity of CYP2C9: Role of B'-C loop residues in providing the π-stacking anchor site for warfarin binding. Biochem 38(11):3285-3292
99. Rao S, Aoyama R, Schrag M, Trager WF, Rettie A, Jones JP (2000) A refined 3-dimensional QSAR of cytochrome P450 2C9: computational predictions of drug interactions. J Med Chem 43(15):2789-2796
100. Kazuya Y, Noriyuki Y, Hiroaki G, Hideki T, Shuichi H (2009) Structure-based CoMFA as a predictive model - CYP2C9 inhibitors as a test case. J Chem Info Modeling 49(4):853-864
101. Robertson AO (1953) PhD Thesis, University of Wisconsin, Madison, WI
102. Ross Montgomery E, Taylor S, Segretario J, Engler E, Sebastian D (1996) Development and validation of a reverse-phase liquid chromatographic method for analysis of aspirin and warfarin in a combinarion tablet formulation. J Pharm Biomed Anal 15:73-82
103. Krishnamurthy K, Ramasivan T, Singh DP (1971) Rodents and their control. VI.I. Effect of impurities in warfarin on its acceptability and mortality to black rats (Rattus rattus). Bull Grain Technol 9(4):252-256
104. Norinder U, Österberg T (2000) The applicability of computational chemistry in the evaluation and prediction of drug transport properties. Perspec Drug Discov Design 19:1-18
105. Ertl P, Rohde B, Selzer P (2000) Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. J MedChem 43(20):3714-3717
106. Bravi G, Wikel JH (2000) Application of MS-WHIM descriptors: 3. Prediction of molecular properties. Quant Struct-Activ Relat 19(1):39-49
107. Emoto C, Murayama N, Rostami-Hodjegan A, Yamazaki H (2009) Utilization of estimated physicochemical properties as an integrated part of predicting hepatic clearance in the early drugdiscovery stage: impact of plasma and microsomal binding. Xenobiotica 39(3):227-235
108. Liao C, Nicklaus MC (2009) Comparison of nine programs predicting pKa values of pharmaceutical substances. J Chem Inf Model 49:2801-2812
109. Box KJ, Völgyi G, Baka E, Stuart M, Takács-Nowák T, Comer JEA (2006) Equilibrium versus kinetic measurements of aqueous solubility, and the ability of compounds to supersaturate in solution-a validation study. J Pharm Sci 95(6):1298-1307
110. Otagiri M, Fokkens JG, Hardee GE, Perrin JH (1978) The interaction of some coumarin anticoagulants with b-cyclodextrin in phosphate buffers. Pharm Acta Helv 53(8):241-247
111. Illum L, Bundgaard H, Davis SS (1983) A constant partition model for examining the sorption of drugs by plastic infusion bags. Int J Pharm 17:183-192
112. Stella VJ, Mooney KG, Pipkin JD (1984) Dissolution and ionization of warfarin. J Pharm Sci 73(7):946-948
113. Opong-Mensah K, Woller TW, Obaseki AO, Porter WR (1984) Chemical and statistical considerations in the determination of partition coefficients of weakly ionizable drugs and poisons. J Pharm Biomed Anal 2(3/4):381-394
114. Walter K, Kurz H (1988) Binding of drugs to human skin: Influencing factors and the role of tissue lipids. J Pharm Pharmacol 40:689-693
115. Baars LGM, Schepers MT, Hermans JJR, Dahlmans HJJ, Thijssen HHW (1990) Enantioselective structure-pharmacokinetic relationships of ring substituted warfarin analogues in the rat. J Pharm Pharmacol 42:861-866
116. Ishihama Y, Oda Y, Asakaw N (1994) Microscale determination of dissociation constants of multivalent pharmaceuticals by capillary electrophoresis. J Pharm Sci 83(10):1500-1507
117. Ishihama Y, Oda Y, Asakaw N (2005) Review report for the active substance warfarin. ec.europa.eu/food/plant/protection/evaluation/existactive/warfarin- en.pdf Downloaded 25Jan2010
118. Völgyi G, Ruiz R, Box K, Comer J, Bosch E, Takács- Novák K (2007) Anal Chim Acta 583:418-428
119. a screening using 3μL of 10 mM DMSO stock. Presented at: LogP2009-the 4th LogP symposium, Feb. 8-11, 2009, ETHZurich, Switzerland